All Title Author
Keywords Abstract


Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects

DOI: 10.4236/asm.2014.41001, PP. 1-5

Keywords: Erectile Dysfunction, Diabetes, Phosphodiesterase Type 5 Inhibitors, Bobo-Dioulasso

Full-Text   Cite this paper   Add to My Lib

Abstract:

Objective: To study erectile dysfunction in diabetic patients seen in two clinics in the city of Bobo-Dioulasso, Burkina Faso. Materials and Methods: A prospective cross-sectional descriptive study was conducted at the Souro Sanou Teaching Hospital (CHUSS) and the Saint Leopold clinic in Bobo-Dioulasso, from March 1 to September 1, 2012. A total of 107 patients data were collated and analysed, which was then grouped into two: the ED group, designating patients with erectile dysfunction and the NED group consisting of those patients without. The sample comprised of 61 patients with types 1 and 2 diabetesand were aged between 25-70 years. The IIEF-5 was used to evaluate erectile dysfunction. Results: The prevalence of erectile dysfunction was 57%. The average age of patients was 54.4 ± 8.3 years. All patients with ED had type 2 diabetes. The mean disease duration of diabetes was 7.2 ± 6 years. Erectile dysfunction was severe in 32.8% of cases, moderate in 31.1% of cases and mild in 36.1%. Its severity was significantly associated with glycated hemoglobin, triglycerides and BMI. Phosphodiesterase types 5 (PDE5) inhibitors were found to be effective in the treatment of erectile dysfunction with a satisfactory therapeutic response in 77.4% of users. Conclusion: Erectile dysfunction is a common complication in diabetic patients. Its occurrence and severity are influenced by several factors. The potential presence of this disorder should be assessed due to its negative impact on quality of life. Phosphodiesterase type 5 inhibitors are an effective treatment modality in diabetic patients.

References

[1]  International Diabetes Federation (IDF), “Diabetes Atlas,” 5th Edition, International Diabetes Federation, Brussels, 2011.
[2]  R. Ma and P. Long, “Dysfonctionnement Erectile Chez les Hommes Atteints de Diabète: Signe Precoce de Cardiopathie,” Diabetes Voice, Vol. 53, No. 3, 2008, pp. 25-27.
[3]  J. Romeo, A. Seftel, Z. Madhun and D. Aron, “Sexual Function in Men with Diabetes Type 2: Association with Glycemic Control,” Journal of Urology, Vol. 163, No. 3, 2000, pp. 788-791.
http://dx.doi.org/10.1016/S0022-5347(05)67805-6
[4]  V. Phé, M. Rouprèt, K. Ferhi, O. Traxer, F. Haab and S. Beley, “Etiologie et Prise en Charge de la Dysfonction Erectile chez le Patient Diabétique,” Progrès en Urologie, Vol. 19, No. 6, 2009, pp. 364-371. http://dx.doi.org/10.1016/j.purol.2009.02.004
[5]  R. C. Rosen, J. C. Cappelleri, M. D. Smith, J. Lipsky and B. M. Pena, “Development and Evaluation of an Abridged, 5-Item Version of the International Index of Erectile Function (IIEF-5) as a Diagnostic Tool for Erectile Dysfunction,” International Journal of Impotence Research, Vol. 11, No. 6, 1999, pp. 319-326.
[6]  H. Awad, A. Salem, A. Gadalla, A. El wafa and O. Mohamed, “Erectile Function in Men with Diabetes Type 2: Correlation with Glycemic Control,” International Journal of Impotence Research, Vol. 22, No. 1, 2010, pp. 36-39. http://dx.doi.org/10.1038/ijir.2009.39
[7]  D. Fedele, A. Bortolotti, C. Coscelli, F. Santeusanio, L. Chatenoud, E. Colli, M. Lavezzari, M. Landoni and F. Parazzini, “Erectile Dysfunction in Type 1 and Type 2 Diabetics in Italy,” International Journal of Epidemiology, Vol. 29, No. 3, 2000, pp. 524-531. http://dx.doi.org/10.1093/ije/29.3.524
[8]  P. Costa, T. Grivel, F. Giuliano, P. Pinton, E. Amar and A. Lemaire, “La Dysfonction Erectile: Un Symptome Sentinelle?” Progrès en Urologie, Vol. 14, 2005, pp. 203-207.
[9]  S. Gueye, S. Diop, M. BA, E. Dagadou, P. Fall, M. Sow and A. Mensah, “La Dysérection Chez le Diabétique. Profil Epidemiologique au Sénégal,” Progrès en Urologie, Vol. 8, 1998, pp. 377-781.
[10]  A. Lokrou, D. P. Koffi, S. Soumahoro, A. Derbé, J. Abodo, A. J. C. Azoh, et al., “Etude Epidémiologique et Clinique de la Dysfonction Erectile du Diabétique noir Africain en Cote d’Ivoire,” Diabetes & Metabolism, Vol. 36, 2010, pp. A40-A109.
[11]  M. D. Azemar, J. Menard, T. Ripert and F. Staerman, “Le Schema Thérapeutique Habituel de la Dysfonction Erectile Est-Il Adapté Après 65 Ans?” Progrès en Urologie, Vol. 19, No. 3, 2009, pp. 202-208. http://dx.doi.org/10.1016/j.purol.2008.11.010
[12]  V. Fonseca, A. Seftel, J. Denne and P. Fredlund, “Impact of Diabetes Mellitus on the Severity of Erectile Dysfunction and Response to Treatment: Analysis of Data from Tadalafil Clinical Trials,” Diabetologia, Vol. 47, No. 11, 2004, pp. 1914-1923. http://dx.doi.org/10.1007/s00125-004-1549-6
[13]  S. Siu, S. Lo, K. Wong, K. M. Ip and Y. Wong, “Prevalence of and Risk Factors for Erectile in Hong Kong Diabetic Patients,” Diabetic Medicine, Vol. 18, No. 9, 2001, pp. 732-738.
http://dx.doi.org/10.1046/j.0742-3071.2001.00557.x
[14]  S. Droupy, “Dysfonction Erectile,” Revue du Praticien, 2010, pp. 685-728.
[15]  Y. El Achhab, M. Berraho, A. Benslimane, M. Chrit, H. El Hassani, B. Lyoussi and C. Nejjari, “Diabète et Dysfonction Erectile au Maroc: Etude Epidemiologique Auprès d’une Population de Consultants,” La Revue de Santé de la Méditerranéeorientale, Vol. 14, No. 5, 2008, pp. 1090-1100.
[16]  B. Diao, A. K. Ndoye, P. A. Fall, Y. Diallo, Y. Sow, B. Fall, L. Niang, A. Odzebe, I. Bah, Y. Sow, M. Ba and B. A. Diagne, “La Dysfunctionerectile au Sénégal: Profil Epidémiologique, ”Androl, Vol. 17, No. 3, 2007, pp. 223-229. http://dx.doi.org/10.1007/BF03040731
[17]  P. Lyngdorf and L. Hemmingsen, “Hemmingsen Epidemiology of Erectile Dysfunction and Its Risk Factors: A Price-Based Study in Denmark,” International Journal of Impotence Research, Vol. 16, No. 2, 2004, pp. 105-111. http://dx.doi.org/10.1038/sj.ijir.3901184
[18]  E. Moreira, L. Lobo, M. Villa, A. Nicolosi and D. Glasser, “Prevalence and Correlates of Erectile Dysfunction in Salvador, Northeastern Brazil: A Population-Based Study,” International Journal of Impotence Research, Vol. 14, Suppl. 2, 2002, pp. S3-S9. http://dx.doi.org/10.1038/sj.ijir.3900892
[19]  R. Rosen, J. Altwein, P. Boyle, S. R Kirby, B. Lukacs, E. Meuleman, et al., “Troubles Urinaires du bas Appareil et Dysfonction Sexuelle Masculine: l’Enquête MSAM-7 ou Enquête Multinationale de l’homme Agé,” Progrès en Urologie, Vol. 14, 2004, pp. 332-344.
[20]  F. Cour, P. Fabbro-Peray, B. Cuzin, M. Bonierbale, P. Bondil, M. Crecy, et al., “Recommandations aux Médecins Généralistes pour la Prise en Charge de Première Intention de la Dysfonction Erectile,” Progrès en Urologie, Vol. 15, 2005, pp. 1011-1020.
[21]  P. Moulik and K. Hardy “Hypertension, Antihypertensive Drug Therapy and Erectile Dysfunction in Diabetes,” Diabetic Medicine, Vol. 20, No. 4, 2003, pp. 290-293. http://dx.doi.org/10.1046/j.1464-5491.2003.00911.x
[22]  A. Allouch and J. J. Legro, “Les Troubles Erectiles Chez les Diabétiques à l’ABD,” Contacts-Diabète-Infos, Bruxelles, Vol. 50, 2002, pp. 935-1180.
[23]  P. Costa, C. Avance and L. Wagner, “Dysfonction Erectile: Connaissances, Souhaits et Attitudes. Résultats D’une Etude Francaise Réalisée Auprès de 5099 Hommes agés de 18 à 70 ans,” Progrès en Urologie, Vol. 13, No. 1, 2003, pp. 85-91.
[24]  F. Giuliano, M. Chevret-Measson, A. Tsatsaris, C. Reitz, M. Murino and P. Thonneau, “Prévalence de L’insuffisance érectile en France: Résultants D’une Enquête EpidéMiologique Menée d’un Echantillon de 1004 Hommes,” Progrès en Urologie, Vol. 12, 2002, pp 260-267.

Full-Text

comments powered by Disqus